Open AccessType 3 diabetes (T3D) and alzheimer’s disease (AD)
Author(s) -
Mahesh Shivananjappa
Publication year - 2022
Publication title -
current trends in pharmacy and pharmaceutical chemistry
Language(s) - English
Resource type - Journals
ISSN - 2582-5062
DOI - 10.18231/j.ctppc.2022.003
Subject(s) - oxidative stress , diabetes mellitus , disease , type 2 diabetes , type 2 diabetes mellitus , amyloid (mycology) , alzheimer's disease , medicine , neuroscience , neurite , neurodegeneration , endocrinology , bioinformatics , biology , pathology , biochemistry , in vitro
Alzheimer’s disease (AD) is being referred as Type-3-Diabetes (T3D) as both have similar molecular and cellular features but it’s still in a debate. Progression of Type 2 Diabetes Mellitus (T2DM) is called AD. AD is also called “diabetes of the brain”.Insulin degrading enzyme (IDE) is very important in the shift of T2DM to T3D. Biochemical and molecular abnormalities of AD are mitochondrial dysfunction, chronic oxidative stress, amyloid-β deposits, neurofibrillary tangles, cell loss, dystrophic neurites, increased activation of signalling pathways and pro-death genes. This review aims to explain all these structural and molecular similarities between T3D and AD.